Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation

Maria Grazia Celeste, Francesca De Marco, Claudio Fresco, Giuseppe Musumeci, Roberto Ravasio

DOI: https://doi.org/10.7175/fe.v18i1.1327


BACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20) are indicated for the prevention of thromboembolic events in patients with Non-Valvular Atrial Fibrillation (NVAF). Outcomes from observational study demonstrated that D150 and R20 reduced the rate of thromboembolic events.

OBJECTIVE: This analysis estimated the budget impact of the use of D150 and R20 for the treatment of NAFV patients in Italy.

METHODS: A budget-impact model (BIM) was developed to estimate the direct costs up to 12 months from an Italian NHS perspective. The resource utilization (drugs and intracranial hemorrhage or major extracranial bleeding event) was derived from an observational study. Only direct medical costs were considered. Ex-factory prices and National Tariffs were considered to estimate the costs of drugs and medical resource used, respectively. The BIM showed the difference of expenditure and clinical events (intracranial hemorrhage or major extracranial bleeding) generated by the base case calculated for current prescription volumes (D150 30%, R20 100%), and for different prescription volume scenarios (D150 at 70% and 100%). Key variables were tested in the sensitivity analysis.

RESULTS: D150 was associated with a medical cost offset driven by fewer intracranial hemorrhage and major extracranial bleeding event, these offset the incremental drug cost and results in an annual saving per patient treated (D150: € 1,052.78; R20: € 1,161.23). The present scenario determines an annual cost of € 262,543,583. The impact of total annual costs for the Italian NHS would be lower if D150 prescription volumes would be higher. The total cost is predicted to decrease by 3.8% if the D150 prescription increase to 70% and it is predicted to decrease by 6.7% if the D150 prescription increase to 100%.

CONCLUSION: The use of D150, as an alternative to R20 to prevent events in patients with NVAF, could represent a cost-saving option for the Italian NHS.


Dabigatran, Rivaroxaban; Non-Valvular Atrial Fibrillation; Budget impact analysis

Full Text



  • Pradaxa – Prescribing Information. Ridgefield, CT: Boehringer Ingelheim; 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022512s011lbl.pdf (last accessed April 2017)
  • Xarelto – Prescribing Information. Leverkusen, Germany: Janssen; 2011. Available at: http://www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf (last accessed April 2017)
  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51; https://doi.org/10.1056/NEJMoa0905561
  • Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91; https://doi.org/10.1056/NEJMoa1009638
  • Rognoni C, Marchetti M, Quaglini S, et al. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig 2014; 34: 9-17; https://doi.org/10.1007/s40261-013-0144-3
  • Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-20; https://doi.org/10.1056/NEJMoa1502000
  • Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices—budget impact analysis. Value Health 2007; 10: 336-47; https://doi.org/10.1111/j.1524-4733.2007.00187.x
  • Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014; 17: 5-14; https://doi.org/10.1016/j.jval.2013.08.2291
  • Graham DJ, Reichman ME, Wernecke M, et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med 2016; 176: 1662-71; https://doi.org/10.1001/jamainternmed.2016.5954
  • ISTAT Popolazione residente 1 gennaio 2016. Available at: http://dati.istat.it/Index.aspx?DataSetCode=DCIS_POPRES1 (last accessed August 2016)
  • Davis RC, Hobbs FD, Kenkre JE, et al. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 2012; 14: 1553-9; https://doi.org/10.1093/europace/eus087
  • IMS Health S.p.A. Estimation from Market Dynamics (IMS) in line with actual trend
  • IMS Health S.p.A. IMS analysis on sold packages in AF market
  • Data on file. IHS Markit
  • Data on file. Boehringer Ingelheim
  • Ravasio R, Pedone MP, Ratti M. Cost efficacy analysis of new oral anticoagulant for stroke prevention in non-valvular atrial fibrillation in Italy. PharmacoEcon Ital Res Artic 2014; 16: 22; https://doi.org/10.1007/s40276-014-0022-x
  • Belisari A, Iannazzo S, Di Pasquale G, et al. Budget impact analysis of idarucizumab for the management of patients treated with dabigatran in emergency / urgent situations in Italy. Farmeconomia. Health economics and therapeutic pathways 2016; 17: 47-58; https://doi.org/10.7175/fe.v17i2.1243
  • Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017; 377: 431-41; https://doi.org/10.1056/NEJMoa1707278
  • Database CORE (Collaborative Outcome Research) CINECA
  • Lip GYH, Larsen TB, Skjøth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012; 60: 738-46; https://doi.org/10.1016/j.jacc.2012.03.019
  • Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012; 5: 480-6; https://doi.org/10.1161/CIRCOUTCOMES.112.965988
  • Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016; 353: i3189; https://doi.org/10.1136/bmj.i3189
  • Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 2016; 25: 1236-44; https://doi.org/10.1002/pds.4034
  • Nielsen PB, Skjøth F, Søgaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510; https://doi.org/10.1136/bmj.j510
  • Peng S, Deger KA, Ustyugova A, et al. Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries. Curr Med Res Opin 2017; 26: 1-9; https://doi.org/10.1080/03007995.2017.1375470


Abstract: 2250 views
HTML: 1416 views
PDF: 388 views


  • There are currently no refbacks.